Why the study?
To evaluate the efficacy and safety of cangrelor compared with clopidogrel in subgroups of patients undergoing PCI that did and did not receive glycoprotein IIb/IIIa inhibitors.
Does cangrelor reduce ischemic complications compared to clopidogrel in patients undergoing PCI, irrespective of glycoprotein IIb/IIIa inhibitor use?
Meta-Analysis (n=24,902)
randomized
Yes
Does cangrelor reduce ischemic complications compared to clopidogrel in patients undergoing PCI, irrespective of glycoprotein IIb/IIIa inhibitor use?
Odds Ratio: 0.82 (95% CI 0.72–0.94)
Absolute Event Rate: 3.6% vs 4.4%
Cangrelor effectively reduces ischemic complications compared to clopidogrel in patients undergoing PCI, with consistent benefits regardless of concomitant glycoprotein IIb/IIIa inhibitor use.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Vaduganathan et al. (2017) conducted a meta-analysis in Percutaneous Coronary Intervention (n=24,902). Cangrelor vs. Clopidogrel was evaluated on Composite of all-cause mortality, myocardial infarction, ischemia-driven revascularization, or stent thrombosis at 48 h after randomization (OR 0.82, 95% CI 0.72 to 0.94).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: